Periotherapia Co., Ltd.
2-8 Yamadaoka, Suita City, Osaka, 565-0871
2-12-11 Nishinakajima, Yodogawa-ku, Osaka City, Osaka, 532-0011
2-2 Yamadaoka, Suita City, Osaka, 565-0871
October 2, 2017
The company is engaged in drug discovery for intractable diseases, with a primary focus on treatment-resistant breast cancer.
12 people (as of April 2025)
10 million yen (as of April 2025)
Company Established
Moved to the Center for Medical Innovation (CoMIT), Graduate School of Medicine, Osaka University
Completed Series A Fundraising
Completed Humanization of Development Candidate Antibody
Completed Series B Fundraising
Completed Series C Fundraising
Completed Clinical Trial Drug Production
Funding Secured
Selected for AMED's "Drug Discovery Venture Ecosystem Strengthening Project"
Signed Joint Research Agreement with Eisai Inc.
Completed Series D Fundraising
Funding implementation
Clinical trials of PT0101 begin at Osaka University Hospital
2-12-11 Nishinakajima, Yodogawa-ku, Osaka City, Osaka, 532-0011
+81-6-7653-4746
+81-6-6459-9199
5 minutes walk from Nishinakajima Minamigata Station on the Osaka Metro Midosuji Line and 6 minutes walk from Minamigata Station on the Hankyu Line
2-2 Yamadaoka, Suita City, Osaka, 565-0871
+81-6-6210-8409
+81-6-6210-8346
Approximately 10 minutes walk from "Handai Byoin-mae Station" on the Osaka Monorail Saito Line
